LONDON--19 Mar--PRNewswire-AsiaNet/InfoQuest AstraZeneca (NYSE: AZN) today announced SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release) clinical trial data presented at the European Congress of Psychiatry (ECP) in Madrid. The data demonstrated that the SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release), administered once daily, significantly improvedsymptoms associated with schizophrenia(1) (measured by PANSS) and increased the time to psychiatric relapse(2), when administered through a 3-step dose initiation aimed at reaching the effective dose range on the second day of treatment. SEROQUEL(R) sustained release formulation is under review by regulatory authorities around the world for the treatment of schizophrenia and has not been approved in any market. A randomized, double-blind study of 588 patients with acute schizophrenia (Study 132) compared SEROQUEL(R) sustained release formulation (400 mg/day, 600 mg/day or 800 mg/day) with placebo and found a significant improvement in Positive and Negative Syndrome Scale (PANSS) total scores from baseline for all doses(1). After 6 weeks of treatment, reductions of 24.8 (p=0.03), 30.9 (p